CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Combination of oxidative phosphorylation and platelet-derived growth factor inhibitors for the treatment of ovarian cancers.
Combination of oxidative phosphorylation and platelet-derived growth factor inhibitors for the treatment of ovarian cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
FDA批准氧化磷酸化抑制剂（二甲双胍和阿托伐醌）与血小板衍生生长因子抑制剂（舒尼替尼和索拉非尼）的联合治疗可靶向卵巢癌干细胞样细胞（CSCs）及癌相关间充质干细胞对CSCs的富集，同时减少脱靶效应。48小时药物暴露的卵巢癌-MSC肿瘤球模型结果显示，阿托伐醌联合舒尼替尼或索拉非尼的叠加效应最为有效。
The combination therapy of FDA approved oxidative phosphorylation inhibitors (metformin and atovaquone) and platelet derived growth factor inhibitors (sunitinib and sorafenib) could target ovarian cancer stem-like cells (CSCs) and carcinoma associated mesenchymal stem cell enrichment of CSCs while reducing off-target effects. Results of a 48-hour drug exposure ovarian cancer-MSC tumoroid model showed additive effects with atovaquone combined with sunitinib or sorafenib being most effective.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
